TCGA-GC-A3RD-01A-12R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.06044678
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.240
- PROTEIN_SECRETION+0.200
- MYC_TARGETS_V2+0.120
- SPERMATOGENESIS+0.070
- PEROXISOME+0.060
- PANCREAS_BETA_CELLS+0.020
- ESTROGEN_RESPONSE_EARLY+0.000
- XENOBIOTIC_METABOLISM-0.030
- IL6_JAK_STAT3_SIGNALING-0.050
- TNFA_SIGNALING_VIA_NFKB-0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- ALLOGRAFT_REJECTION-0.390
- WNT_BETA_CATENIN_SIGNALING-0.370
- INTERFERON_GAMMA_RESPONSE-0.360
- MYC_TARGETS_V1-0.300
- COMPLEMENT-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- HEDGEHOG_SIGNALING-0.290
- NOTCH_SIGNALING-0.290
- TGF_BETA_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | aMVAC.P_005_TURBT_S223 | — | — | 0.833 |
| 2 | SRR1348021 | GTEX | — | 0.833 |
| 3 | TCGA-CF-A27C-01A-11R-A16R-07 | — | — | 0.830 |
| 4 | SRR8943038 | — | — | 0.826 |
| 5 | SRR1341605 | GTEX | — | 0.826 |
| 6 | SRR1467813 | GTEX | — | 0.825 |
| 7 | SRR1338669 | GTEX | — | 0.824 |
| 8 | SRR25617918 | — | B | 0.821 |
| 9 | SRR1436444 | GTEX | — | 0.820 |
| 10 | SRR1404969 | GTEX | — | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |